Abstract
Dermatomycosis are fungal infections that involve the stratum corneum of the skin and the nails, hair, and surfaces of mucous membranes. Mycological infections represent important public health disorders, and their incidence has increased in recent years. This increase may result from a number of causes, such as an increase in the susceptible population, including the elderly and immunodeficient, and social and cultural exchanges associated with sports and the use of swimming pools. In immunodeficient individuals, the lesions associated with dermatomycosis are more intense, and what are initially superficial lesions can result in disseminated and fatal forms. The primary reasons for this include antifungal resistance, toxicity, lack of rapid and specific diagnoses and the poor penetration of drugs. The currently available antifungal agents for the treatment of dermatomycosis include azole and the allylamine group of drugs. The problems related to dermatomycosis therapy are the low residence times of the dosage forms in the site of action, side effects and variable drug permeability. Thus, novel topical drug delivery systems for antifungal therapy have been developed, including liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, silver nanoparticles, microemulsion and liquid crystals. The objective of this study is to present a systematic review of nanotechnology-based drug delivery systems for dermatomycosis treatment.
Keywords: Dermatomycosis, drug delivery systems, nanotechnology
Current Nanoscience
Title:Nanotechnology-based Drug Delivery Systems for Dermatomycosis Treatment
Volume: 8 Issue: 4
Author(s): Ana Luiza Ribeiro de Souza, Charlene Priscila Kiill, Fernanda Kolenyak dos Santos, Gabriela Marielli da Luz, Hilris Rocha e Silva, Marlus Chorilli and Maria Palmira Daflon Gremiao
Affiliation:
Keywords: Dermatomycosis, drug delivery systems, nanotechnology
Abstract: Dermatomycosis are fungal infections that involve the stratum corneum of the skin and the nails, hair, and surfaces of mucous membranes. Mycological infections represent important public health disorders, and their incidence has increased in recent years. This increase may result from a number of causes, such as an increase in the susceptible population, including the elderly and immunodeficient, and social and cultural exchanges associated with sports and the use of swimming pools. In immunodeficient individuals, the lesions associated with dermatomycosis are more intense, and what are initially superficial lesions can result in disseminated and fatal forms. The primary reasons for this include antifungal resistance, toxicity, lack of rapid and specific diagnoses and the poor penetration of drugs. The currently available antifungal agents for the treatment of dermatomycosis include azole and the allylamine group of drugs. The problems related to dermatomycosis therapy are the low residence times of the dosage forms in the site of action, side effects and variable drug permeability. Thus, novel topical drug delivery systems for antifungal therapy have been developed, including liposomes, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, silver nanoparticles, microemulsion and liquid crystals. The objective of this study is to present a systematic review of nanotechnology-based drug delivery systems for dermatomycosis treatment.
Export Options
About this article
Cite this article as:
Luiza Ribeiro de Souza Ana, Priscila Kiill Charlene, Kolenyak dos Santos Fernanda, Marielli da Luz Gabriela, Rocha e Silva Hilris, Chorilli Marlus and Palmira Daflon Gremiao Maria, Nanotechnology-based Drug Delivery Systems for Dermatomycosis Treatment, Current Nanoscience 2012; 8 (4) . https://dx.doi.org/10.2174/157341312801784311
DOI https://dx.doi.org/10.2174/157341312801784311 |
Print ISSN 1573-4137 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6786 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells
Current Drug Targets Standardization of Procedures for the Preparation of <sup>177</sup>Lu- and <sup>90</sup>Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation
Current Radiopharmaceuticals A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Current Vascular Pharmacology Camptothecins and Lung Cancer: Improved Delivery Systems by Aerosol
Current Cancer Drug Targets TH2 Cytokines and Associated Transcription Factors as Therapeutic Targets in Asthma
Current Drug Targets - Inflammation & Allergy Oncogenic Signaling in Acute Myeloid Leukemia
Current Drug Targets NF-κB Signaling and Carcinogenesis
Current Pharmaceutical Design Advances in the Management of Malignant Hemopathies: The Role of Statins
Recent Patents on DNA & Gene Sequences Redox-active and Redox-silent Compounds: Synergistic Therapeutics in Cancer
Current Medicinal Chemistry Prevention and Treatment of Regimen-Related Mucosal Toxicity
Recent Patents on Anti-Cancer Drug Discovery Deregulation of Apoptosis - Is it Still an Important Issue in Pathogenesis of Chronic Lymphocytic Leukemia?
Current Cancer Drug Targets Current Targets for Anticancer Drug Discovery
Current Drug Targets Urokinase Receptor (uPAR) Ligand based Recombinant Toxins for Human Cancer Therapy
Current Pharmaceutical Design NF-κB Down–regulation and PARP Cleavage by novel 3-α-butyryloxy-β-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression
Anti-Cancer Agents in Medicinal Chemistry Na<sup>+</sup>/K<sup>+</sup> ATPase Inhibitors in Cancer
Current Drug Targets Onconeural Versus Paraneoplastic Antigens?
Current Medicinal Chemistry Polymorphisms in Methotrexate Pathways: What Is Clinically Relevant, What Is Not, and What Is Promising
Current Drug Metabolism Editorial [Hot Topic:Epigenetic Mechanisms and Therapeutic Strategies (Guest Editors: Victoria Samanidou and Leda Kovatsi)]
Current Medicinal Chemistry Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology Low Dose Chest Computed Tomography, in Identifying Pulmonary Complications in Immunocompromised Patients After Allogeneic Hematopoietic Stem Cell Transplantation
Current Respiratory Medicine Reviews